Cover Image

U.S. Market for Minimally Invasive Bariatric Surgical Devices

An estimated 200 million adults in the U.S. (a staggering 68% of the adult population) are categorized as overweight or obese. Obesity is the, second-leading cause of preventable death in the U.S. resulting in nearly 112,000 deaths annually. The condition is a leading cause of type 2 diabetes, disability, and heart disease, and is a significant contributor to rising healthcare costs. Despite the dire need for weight loss in the majority of the adult population, research has found that diet and exercise alone is unsuccessful in 80-85% of patients at one year, and only approximately 1% of the eligible obese population currently undergoes bariatric surgery due to high cost and high risk of complications. This presents a significant unmet need for less invasive weight loss treatments. Although more clinical research is required, minimally invasive bariatric surgical devices and systems may provide a less costly, safe and effective - and potentially lifesaving - weight loss alternative.

While current economic conditions continue to restrain market growth, the U.S. market for minimally invasive bariatric surgical devices is expected to exhibit relatively strong growth over the next 5 years. Valued at more than $345 million in 2010, the U.S. minimally invasive bariatric surgical products market is expected to increase at a healthy compound annual rate of 6.6%, with sales reaching more than $500 million in 2016.

The market is expected to benefit from increased utilization of laparoscopic adjustable gastric banding systems and emerging incisionless technologies, including intragastric balloons and other transorally inserted weight loss devices, as well as implantable gastric stimulators or vagal blocking systems. The market is also expected to benefit from growing usage of single-incision surgery; minimally invasive robotic surgery is also expected to continue to significantly improve bariatric surgical outcomes.

This dynamic report from Medtech Insight includes analyses of products, markets, competitors, and emerging technology and opportunities. Covered topics in this report include laparoscopic adjustable gastric banding (LAGB) systems; intragastric balloon systems; emerging transorally inserted weight loss devices; single-incision technologies; minimally invasive robotic systems; and implantable gastric stimulation/vagal blocking systems.

Table of Contents

EXECUTIVE SUMMARY

  • i. Causes of Obesity
  • ii. Health Risks
  • iii. Statistics
  • iv. Minimally Invasive Bariatric Surgical Devices Market
  • v. Methodology
  • Exhibit ES-1: Body Mass Index and Obesity
  • Exhibit ES-2: Surgeon General' s Call to Action to Prevent and Decrease Overweight and Obesity
  • Exhibit ES-3: Trends in Overweight, Obesity, and Morbid Obesity, 1988-2008
  • Exhibit ES-4: Trends in Overweight, Obesity, and Morbid Obesity, 1960-2008
  • Exhibit ES-5: Prevalence of Obesity Among Men, by Race/Ethnicity, 1988-1994 and 2007-2008
  • Exhibit ES-6: Prevalence of Obesity Among Women, by Race/Ethnicity, 1988-1994 and 2007-2008
  • Exhibit ES-7: Minimally Invasive Bariatric Surgery, Procedure Volumes Forecast, 2010-2016
  • Exhibit ES-8: Minimally Invasive Bariatric Surgical Devices, Combined Market Forecast, by Segment, 2010-2016

1. CLINICAL OVERVIEW OF OBESITY

  • 1.1 Causes of Obesity
    • 1.1.1 Calorie Intake
    • 1.1.2 Genetics
    • 1.1.3 Behavior and Environment
    • 1.1.4 Diseases/Disorders and Drug Use
  • 1.2 Health Risks
    • 1.2.1 Diabetes
    • 1.2.2 Cancer
  • 1.3 Statistics
  • Exhibit 1-1: Body Mass Index and Obesity
  • Exhibit 1-2: Surgeon General' s Call to Action to Prevent and Decrease Overweight and Obesity
  • Exhibit 1-3: Comorbidities of Obesity
  • Exhibit 1-4: Trends in Overweight, Obesity, and Morbid Obesity, 1988-2008
  • Exhibit 1-5: Trends in Overweight, Obesity, and Morbid Obesity, 1960-2008
  • Exhibit 1-6: Prevalence of Obesity Among Men, by Race/Ethnicity, 1988-1994 and 2007-2008
  • Exhibit 1-7: Prevalence of Obesity Among Women, by Race/Ethnicity, 1988-1994 and 2007-2008
  • Exhibit 1-8: 2007, Prevalence of Obesity Among Adults, by State

2. GASTRIC BANDING AND INTRAGASTRIC BALOON SYSTEMS

  • 2.1 Laparoscopic Adjustable Gastric Banding
    • 2.1.1 Allergan
    • 2.1.2 Ethicon Endo-Surgery/Johnson & Johnson
    • 2.1.3 Others
      • 2.1.3.1 Agency for Medical Innovations
      • 2.1.3.2 Cousin Biotech
      • 2.1.3.3 Helioscopie
      • 2.1.3.4 Medical Innovation Developpement
  • 2.2 Intragastric Balloons
    • 2.2.1 Allergan
    • 2.2.2 Helioscopie
    • 2.2.3 Reshape Medical
    • 2.2.4 Spatz FGIA
  • 2.3 Market Analysis, Laparoscopic Adjustable Gastric Banding
    • 2.3.1 Procedure Volumes Forecast
    • 2.3.2 Market Forecast
      • 2.3.2.1 Market Drivers
      • 2.3.2.2 Market Limiters
    • 2.3.3 Competitive Analysis
  • 2.4 Market Analysis, Intragastric Balloon Systems
  • Exhibit 2-1: Risks Associated with Gastric Banding and Abdominal/Bariatric Surgery
  • Exhibit 2-2: 2011, Selected Laparoscopic Adjustable Gastric Banding Devices
  • Exhibit 2-3: Allergan' s LAP-BAND AP Adjustable Gastric Banding System
  • Exhibit 2-4: Key Benefits and Risks of the LAP-BAND Procedure
  • Exhibit 2-5: Excess Weight Loss with the LAP-BAND System Compared to Roux-en-Y Gastric Bypass at Three Years and Beyond
  • Exhibit 2-6: Allergan' s EasyBand Remote Adjustable Gastric Band System
  • Exhibit 2-7: Ethicon Endo-Surgery' s Realize Adjustable Gastric Band
  • Exhibit 2-8: Pressure Comparison of the Realize Band Balloon with the LAP-BAND System
  • Exhibit 2-9: Comparison of Gastric Banding, Gastric Bypass, and Sleeve Gastrectomy
  • Exhibit 2-10: Effects of the Realize Adjustable Gastric Banding on Obesity-Related Conditions
  • Exhibit 2-11: Ethicon Endo-Surgery' s Realize Band-C Adjustable Gastric Band
  • Exhibit 2-12: Agency for Medical Innovations' Soft Gastric Band
  • Exhibit 2-13: Cousin Biotech' s Bioring Adjustable Gastric Band
  • Exhibit 2-14: Helioscopie' s Heliogast Adjustable Gastric Band
  • Exhibit 2-15: Medical Innovation Developpement' s MIDBAND Adjustable Gastric Band
  • Exhibit 2-16: Allergan' s Orbera Managed Weight Loss System
  • Exhibit 2-17: Helioscopie' s Heliosphere Intragastric Balloon
  • Exhibit 2-18: ReShape Duo Intragastric Balloon System
  • Exhibit 2-19: The Spatz Adjustable Balloon System
  • Exhibit 2-20: Risks of Intragastric Balloon Placement
  • Exhibit 2-21: The Spatz Adjustable Balloon Procedure
  • Exhibit 2-22: Laparoscopic Adjustable Gastric Banding, Procedure Volumes Forecast, 2010-2016
  • Exhibit 2-23: Laparoscopic Adjustable Gastric Banding, Market Forecast, 2010-2016
  • Exhibit 2-24: 2010, Laparoscopic Adjustable Gastric Banding Systems Market, Share by Supplier
  • Exhibit 2-25: Intragastric Balloon Therapy, Procedure Volumes Forecast, 2010-2016
  • Exhibit 2-26: Intragastric Balloon Systems, Market Forecast, 2010-2016

3. TRANSORAL I NCISIONLESS WEIGHT LOSS TECHNOLOGIES AND DEVICES

  • 3.1 Selected Products
    • 3.1.1 EndoGastric Solutions
    • 3.1.2 GI Dynamics
    • 3.1.3 Satiety
    • 3.1.4 USGI Medical
  • Exhibit 3-1: Emerging Trends in Minimally Invasive/Incisionless Surgery
  • Exhibit 3-2: EndoGastric Solutions' StomaphyX Transoral Fastener Delivery System
  • Exhibit 3-3: GI Dynamic' s EndoBarrier Gastrointestinal Liner and Procedure
  • Exhibit 3-4: GI Dynamic' s EndoBarrier Gastrointestinal Liner Combined with the EndoBarrier Flow Restrictor
  • Exhibit 3-5: Steps of a Transoral Gastroplasty (or TOGA) Procedure
  • Exhibit 3-6: USGI Medical' s Incisionless Operating Platform
  • Exhibit 3-7: Primary Obesity Surgery, Endolumenal and Repair of Surgery, Endolumenal

4. SINGLE-PORT ACCESS SURGERY

  • 4.1 Single-Incision Bariatric Surgery
  • 4.2 Natural Orifice Transluminal Endoscopic Surgery
  • 4.3 Procedure Volumes
  • 4.4 Patient Outcomes
  • 4.5 Economics and Consumer Demand
  • 4.6 Selected Products
    • 4.6.1 Applied Medical Resources
    • 4.6.2 Covidien
    • 4.6.3 Ethicon Endo-Surgery/Johnson & Johnson
    • 4.6.4 Olympus America/Olympus and Advanced Surgical Concepts
    • 4.6.5 TransEnterix
    • 4.6.6 USGI Medical
  • Exhibit 4-1: Selected Advantages of Single-Port Access Surgery
  • Exhibit 4-2: Procedures Employing Single-Port Access
  • Exhibit 4-3: Selected Laparoscopic Procedures that Could Benefit from the Use of Single-Port Access, Procedure Volumes Forecast, 2010-2016
  • Exhibit 4-4: Factors Impacting the Adoption of Single-Port Access Surgery
  • Exhibit 4-5: Applied Medical Resources' GelPOINT Advanced Access Platform
  • Exhibit 4-6: Applied Medical Resources' Premium Disposable Trocar, Kii GelPort Balloon Trocar, and Universal Seal
  • Exhibit 4-7: Covidien' s SILS Port
  • Exhibit 4-8: Covidien' s SILS Stitch Articulating Suturing Device
  • Exhibit 4-9: Ethicon Endo-Surgery' s ENDOPATH XCEL Bladeless Trocar
  • Exhibit 4-10: Ethicon Endo-Surgery' s Single-Site Laparoscopy Access System
  • Exhibit 4-11: Olympus America' s Deflectable-Tip EndoEYE Video Laparoscope
  • Exhibit 4-12: Advanced Surgical Concepts' TriPort Multiport Access Device
  • Exhibit 4-13: Advanced Surgical Concepts' QuadPort Multiport Access Device
  • Exhibit 4-14: TransEnterix' s SPIDER Surgical System
  • Exhibit 4-15: USGI Medical' s Incisionless Operating Platform

5. ROBOTIC-ASSISTED MINIMALLY INVASIVE SURGERY

  • 5.1 Intuitive Surgical
    • 5.1.1 The da Vinci Surgical System
      • 5.1.1.1 The Da Vinci Gastric Bypass
    • 5.1.2 Robotic-Assisted Minimally Invasive Surgery, Market Analysis
  • Exhibit 5-1: Selected Procedures Facilitated by the da Vinci Surgical System
  • Exhibit 5-2: Intuitive Surgical' s da Vinci S HD Surgical System
  • Exhibit 5-3: Intuitive Surgical' s da Vinci Si HD Surgical System
  • Exhibit 5-4: Intuitive Surgical' s EndoWrist Instrument
  • Exhibit 5-5: Comparison of the da Vinci Gastric Bypass Procedure with the Open Surgical Technique
  • Exhibit 5-6: Intuitive Surgical' s Revenues and Unit Sales, 2009 and 2010
  • Exhibit 5-7: Procedures that Employ Intuitive Surgical' s da Vinci Surgical System
  • Exhibit 5-8: Targeted Procedures for which the da Vinci Surgical System May Be Employed
  • Exhibit 5-9: Robotic-Assisted Minimally Invasive Surgical Systems, Market Forecast, 2010-2016

6. IMPLANTABLE GASTRIC STIMULATION DEVICES

  • 6.1 Selected Products
    • 6.1.1 EnteroMedics
    • 6.1.2 IntraPace
    • 6.1.3 MetaCure
    • 6.1.4 Others
      • 6.1.4.1 Cyberonics and Ethicon Endo-Surgery/Johnson & Johnson
      • 6.1.4.2 Leptos Biomedical
      • 6.1.4.3 Medtronic
      • 6.1.4.4 St. Jude Medical
  • 6.2 Market Analysis
  • Exhibit 6-1: 2011, Selected Emerging Implantable Pulse Generators for the Treatment of Obesity
  • Exhibit 6-2: EnteroMedics' Maestro System
  • Exhibit 6-3: Overview of EnteroMedics' VBLOC Therapy and Vagus Nerve Function
  • Exhibit 6-4: Potential Benefits and Risks of VBLOC Therapy
  • Exhibit 6-5: Comparison of VBLOC Therapy, Laparoscopic Banding, and Gastric Bypass
  • Exhibit 6-6: EMPOWER Study, 24-Month Weight Loss Results
  • Exhibit 6-7: VBLOC-DM2 Study, 12-Month Weight Loss Results
  • Exhibit 6-8: VBLOC RF2 Study, 24-Month Weight Loss Results
  • Exhibit 6-9: IntraPace' s abiliti Gastric Stimulation System
  • Exhibit 6-10: MetaCure' s TANTALUS Gastric Stimulation System
  • Exhibit 6-11: Medtronic' s Enterra Neurostimulator
  • Exhibit 6-12: St. Jude Medical' s Eon Mini Neurostimulator
  • Exhibit 6-13: Implantable Gastric Stimulation/VBLOC Therapy Devices, Unit Sales Forecast, 2010-2016
  • Exhibit 6-14: Implantable Gastric Stimulation/VBLOC Therapy Devices, Market Forecast, 2010-2016

7. COMPANY PROFILES

  • 7.1 Allergan, Inc.
  • 7.2 Covidien PLC
  • 7.3 EndoGastric Solutions, Inc.
  • 7.4 EnteroMedics, Inc.
  • 7.5 GI Dynamics, Inc.
  • 7.6 Intuitive Surgical, Inc.
  • 7.7 Johnson & Johnson
  • 7.8 ReShape Medical, Inc.
  • 7.9 Satiety, Inc.
  • 7.10 Spatz FGIA, Inc.
  • 7.11 TransEnterix, Inc.
  • 7.12 USGI Medical, Inc.PPENDIX COMPANY LI
Show More
Pricing
Get Notified
Email me when related reports are published